Ron Bentsur Buys 20,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur acquired 20,000 shares of the business’s stock in a transaction on Friday, November 15th. The shares were purchased at an average cost of $4.92 per share, for a total transaction of $98,400.00. Following the completion of the transaction, the chief executive officer now owns 3,266,424 shares in the company, valued at approximately $16,070,806.08. This represents a 0.62 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Nuvectis Pharma Price Performance

Shares of NVCT opened at $5.07 on Thursday. The business’s 50 day moving average price is $7.07 and its 200-day moving average price is $6.76. Nuvectis Pharma, Inc. has a 52 week low of $4.75 and a 52 week high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. During the same quarter in the previous year, the business earned ($0.37) earnings per share. On average, analysts forecast that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Nuvectis Pharma in a research report on Tuesday, August 6th.

Hedge Funds Weigh In On Nuvectis Pharma

A number of hedge funds have recently added to or reduced their stakes in NVCT. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Nuvectis Pharma during the 2nd quarter valued at $58,000. Nations Financial Group Inc. IA ADV purchased a new stake in Nuvectis Pharma in the 3rd quarter worth $63,000. Baxter Bros Inc. purchased a new position in shares of Nuvectis Pharma during the second quarter valued at about $79,000. GSA Capital Partners LLP grew its position in shares of Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock valued at $315,000 after purchasing an additional 1,790 shares in the last quarter. Finally, Iridian Asset Management LLC CT purchased a new position in shares of Nuvectis Pharma during the third quarter valued at about $348,000. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.